| Literature DB >> 23869101 |
Nnaemeka U Odo1, Jeffrey H Mandel, David M Perlman, Bruce H Alexander, Paul D Scanlon.
Abstract
OBJECTIVES: (1) To assess the impact of American Thoracic Society and European Respiratory Society (ATS/ERS) 'acceptability' and 'usability' criteria for spirometry on the estimates of restrictive ventilatory defect in a population of taconite miners. (2) To compare estimates of restrictive ventilatory defect with three different pulmonary function tests (spirometry, alveolar volume (VA) and diffusing capacity (DL,CO)). (3) To assess the role of population characteristics on these estimates.Entities:
Keywords: Epidemiology; Occupational & Industrial Medicine; Public Health; Respiratory Medicine (see Thoracic Medicine); Statistics & Research Methods
Year: 2013 PMID: 23869101 PMCID: PMC3717471 DOI: 10.1136/bmjopen-2013-002561
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Different categories based on meeting ATS/ERS guidelines on acceptability and repeatability of spirometric evaluations
| Participant manoeuvre | Category | Frequency | Percentage |
|---|---|---|---|
| One acceptable manoeuvre only | 1 | 33 | 3 |
| Two acceptable, repeatable manoeuvres only | 2 | 45 | 4.2 |
| Two acceptable, not repeatable | 3 | 27 | 2.5 |
| Two highest acceptable not repeatable* | 4 | 41 | 3.8 |
| No plateau end-point reached | 5 | 384 | 35.4 |
| No acceptable manoeuvre | 6 | 7 | 0.6 |
| Not repeatable (3 acceptable manoeuvres)† | 7 | 28 | 2.6 |
| Meets ATS criteria | 8 | 519 | 47.9 |
| Total | 1084 | 100 |
‘No plateau end-point reached’ referred to the inability to achieve end-of-test volume (EOTV), an important end-of-test (EOT) criterion. In this case, the volume–time plateau was not obtained.
*Attained three acceptable manoeuvres but, as per criteria, the two highest values were not repeatable. The lower two were repeatable and their values were used.
†Attained three acceptable manoeuvres but, as per criteria, none were repeatable.
ATS/ERS, American Thoracic Society and European Respiratory Society.
Demographic characteristics of four test groups
| Parameters | Group 1 (total group) (n=1084) | Group 2 (exclusions) (n=565) | Group 3 (met criteria) (n=519) | Group 4 (usable) (n=989) |
|---|---|---|---|---|
| BMI* | 31.4 (5.4)† | 31.2 (5.2)† | 31.6 (5.6)† | 31.4 (5.4)† |
| <18.5 | 0.2 | 0.2 | 0.2 | 0.2 |
| 18.5–25 | 8.0 | 7.6 | 8.6 | 8.2 |
| 25–29.9 | 37.6 | 39.6 | 35.5 | 37.5 |
| 30–34.9 | 32.6 | 31.3 | 33.4 | 32.4 |
| 35–39.9 | 13.7 | 14.0 | 13.9 | 14.0 |
| ≥40 | 7.9 | 7.3 | 8.4 | 7.7 |
| Age | 59.7 (10.8)† | 62.2 (9.9)† | 57.0 (11.1)† | 59.2 (10.7)† |
| <50 | 16.5 | 9.6 | 22.9 | 17.3 |
| 50–64 | 49.2 | 46.9 | 51.2 | 50.1 |
| 65–79 | 31.4 | 40.5 | 22.9 | 29.9 |
| >79 | 2.9 | 3.0 | 3.1 | 2.7 |
| Smoking | ||||
| Never | 38.0 | 27.5 | 48.4 | 37.8 |
| Current | 12.0 | 14.9 | 9.2 | 12.5 |
| Former | 50.0 | 57.6 | 42.4 | 49.7 |
| Gender | ||||
| Female | 9.3 | 4.4 | 14.6 | 9.9 |
| Male | 90.7 | 95.6 | 85.4 | 90.1 |
All values were percentage distributions of each parameter within the population groups.
Group 1—all workers surveyed without consideration for exclusion based on ATS/ERS test criteria for spirometry.
Group 2—all workers who did not meet all ATS/ERS criteria for spirometric assessment.
Group 3—workers who met all ATS/ERS criteria for spirometric assessment.
Group 4—All workers with spirometry quality ≥“B” (see Methods section) and repeatable tests not meeting end-of-test (EOT) criteria.
*BMI—weight in kilograms/height in metres squared (kg/m2).
†These represented the mean and SDs (in parenthesis) for these groups.
ATS/ERS, American Thoracic Society and European Respiratory Society; BMI, body mass index.
Prevalence estimates of lung function patterns in different groups
| Group 1 (total group) | Group 2 (exclusions) | Group 3 (met criteria) | Group 4 (usable) | |||||
|---|---|---|---|---|---|---|---|---|
| 1084 | 565 | 519 | 989 | |||||
| N | Per cent | 95% CI | Per cent | 95% CI | Per cent | 95% CI | Per cent | 95% CI |
| Spirometric obstruction* | 16.8 | 14.6 to 19.2 | 27.6 | 24.0 to 31.5 | 5.0 | 3.3 to 7.3 | 17.6 | 15.3 to 20.1 |
| Spirometric restriction* | 4.5 | 3.4 to 5.9 | 3.2 | 1.9 to 5.0 | 6.0 | 4.1 to 8.4 | 3.9 | 2.8 to 5.4 |
| Mixed disease* | 2.9 | 2.0 to 4.0 | 4.6 | 3.0 to 6.7 | 1.0 | 0.3 to 2.2 | 2.9 | 2.0 to 4.2 |
| All spirometric restriction* | 7.4 | 5.8 to 9.1 | 7.8 | 5.7 to 10.3 | 6.9 | 4.9 to 9.5 | 6.9 | 5.4 to 8.6 |
| VA restriction* | 5.9 | 4.6 to 7.5 | 5.0 | 3.3 to 7.1 | 6.9 | 4.9 to 9.5 | 5.7 | 4.3 to 7.3 |
| Low DL,CO without obstruction* | 9.0 | 7.4 to 10.9 | 8.3 | 6.2 to 10.9 | 9.8 | 7.4 to 12.7 | 9.2 | 7.5 to 11.2 |
| Spirometry & VA† | 2.6 | 1.7 to 3.7 | 1.8 | 0.9 to 3.2 | 3.5 | 2.1 to 5.4 | 2.4 | 1.6 to 3.6 |
| Spirometry & DL,CO‡ | 1.3 | 0.7 to 2.2 | 0.7 | 0.2 to 1.8 | 1.9 | 0.9 to 3.5 | 1.2 | 0.6 to 2.1 |
| VA & DL,CO § | 2.3 | 1.5 to 3.4 | 1.4 | 0.6 to 2.8 | 3.3 | 1.9 to 5.2 | 2.3 | 1.5 to 3.5 |
| Spirometry & VA & DL,CO¶ | 1.1 | 0.5 to 1.9 | 0.5 | 0.1 to 1.5 | 1.7 | 0.8 to 3.3 | 1.0 | 0.5 to 1.9 |
| Spirometry or VA** | 7.8 | 6.3 to 9.6 | 6.4 | 4.5 to 8.7 | 9.4 | 7.1 to 12.3 | 7.2 | 5.7 to 9.0 |
| Spirometry or DL,CO†† | 12.3 | 10.4 to 14.4 | 10.8 | 8.4 to 13.7 | 13.9 | 11.0 to 17.2 | 11.9 | 10.0 to 14.1 |
| VA or DL,CO‡‡ | 12.6 | 10.7 to 14.8 | 11.9 | 9.3 to 14.8 | 13.5 | 10.7 to 16.7 | 12.5 | 10.5 to 14.8 |
| Spirometry or VA or DL,CO§§ | 14.4 | 12.6 to 16.6 | 13.1 | 10.4 to 16.2 | 15.8 | 12.8 to 19.2 | 13.9 | 11.8 to 16.2 |
Per cent—prevalence of lung function patterns in each population group in percentage.
95% CI—Clopper-Pearson (exact) 95% confidence limits of prevalence estimates.
Group definitions are as described in the Methods section.
*Definitions described in the Methods section.
†After excluding spirometric obstruction, both FVC and VA were
‡This is the proportion of spirometric restriction that also had a reduced (
§This is the proportion of VA restriction that also had a reduced (
¶After excluding spirometric obstruction, FVC, VA and DL,CO were
**After exclusion of spirometric obstruction, either FVC or VA were
††After exclusion of spirometric obstruction, either FVC or DL,CO were
‡‡After exclusion of spirometric obstruction, either VA or DL,CO were
§§After exclusion of spirometric obstruction, either FVC or VA or DL,CO were
DL,CO, diffusing capacity; FVC, forced vital capacity; LLN, ; VA, alveolar volume.
Linear regression of forced vital capacity (centiles*) by body mass indices (BMIs)
| Test criteria groups | Estimate | R2 (%) |
|---|---|---|
| Group 1† (total group) | −0.018 | 9.1 |
| Group 2‡ (exclusions) | −0.019 | 9.2 |
| Group 3§ (met criteria) | −0.017 | 9.0 |
| Group 4¶ (usable) | −0.017 | 8.8 |
All crude and multivariate linear regression models had significant p values at <0.0001.
Multivariate models involved adjusting for age and gender.
Groups are as described in the Methods Section.
*centiles of spirometry performance are expressed as the FVC of each participant, standardised to the NHANES III population-based distribution of normal lung function. This is different from percentage predicted which is the ratio of the FVC to the median predicted value for each participant (race, age, height and gender adjusted).
†Adjusted estimate: −0.018; R2 (%): 9.5.
‡Adjusted estimate: −0.019; R2 (%): 9.5.
§Adjusted estimate: −0.016; R2 (%): 10.6.
¶Adjusted estimate: −0.017; R2 (%): 9.3.
FVC, forced vital capacity.